Payment overview · 2025
General Payments
$130.86
6 reported records · 3 companies
Healthcare provider profile · identity verified
Brandy C Watson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PALESTINE, TX · NPI 1790996239
Verified facts
What the public records show
CMS Open Payments records show Brandy C Watson, M.D. received $130.86 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 59.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.95 | 59.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.36 | 24.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.55 | 15.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.86 | 5 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 150 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
150 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 69 |
| Omeprazole | Omeprazole | 281 | 78 |
| Eliquis | Apixaban | 253 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 85 |
| Furosemide | Furosemide | 204 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 55 |
| Gabapentin | Gabapentin | 174 | 50 |
| Alprazolam | Alprazolam | 172 | 34 |
| Losartan Potassium | Losartan Potassium | 167 | 43 |
| Metformin Hcl | Metformin Hcl | 158 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 51 |
| Jardiance | Empagliflozin | 150 | 38 |
| Potassium Chloride | Potassium Chloride | 140 | 38 |
| Lisinopril | Lisinopril | 137 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 36 |
| Mounjaro | Tirzepatide | 105 | 22 |
| Carvedilol | Carvedilol | 102 | 38 |
| Meloxicam | Meloxicam | 102 | 38 |
| Montelukast Sodium | Montelukast Sodium | 100 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 18 |
| Sertraline Hcl | Sertraline Hcl | 92 | 14 |
| Simvastatin | Simvastatin | 90 | 26 |
| Tramadol Hcl | Tramadol Hcl | 90 | 31 |
| Mirtazapine | Mirtazapine | 84 | 16 |
| Ozempic | Semaglutide | 81 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 31 |
| Trazodone Hcl | Trazodone Hcl | 71 | 24 |
| Famotidine | Famotidine | 68 | 22 |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Prednisone | Prednisone | 63 | 24 |
| Donepezil Hcl | Donepezil Hcl | 62 | 15 |
| Allopurinol | Allopurinol | 61 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 28 |
| Levetiracetam | Levetiracetam | 61 | suppressed |
| Methocarbamol | Methocarbamol | 57 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 22 |
| Temazepam | Temazepam | 56 | 21 |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Pregabalin | Pregabalin | 54 | 13 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 14 |
| Bumetanide | Bumetanide | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 17 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 17 |
| Metformin Hcl Er | Metformin Hcl | 49 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 13 |
| Ezetimibe | Ezetimibe | 45 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 13 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 14 |
| Atenolol | Atenolol | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Celecoxib | Celecoxib | 34 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 20 |
| Folic Acid | Folic Acid | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Glimepiride | Glimepiride | 29 | 12 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Armour Thyroid | Thyroid,pork | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Finasteride | Finasteride | 24 | 11 |
| Glipizide | Glipizide | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 16 |
| Cephalexin | Cephalexin | 22 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 21 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 11 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Lithium Carbonate | Lithium Carbonate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Multaq | Dronedarone Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.86 · 6 records | Lilly USA, LLC | CREON, JARDIANCE, LINZESS, MOUNJARO, Ozempic, Rybelsus, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error